Citations

Mayo Clinic

Showing 10 of 108602 citations.

Do Quantitative Levels of Anti-Spike-IgG Antibodies Aid in Predicting Protection from SARS-CoV-2 Infection? Results from a Longitudinal Study in a Police Cohort
Sendi, Parham , Widmer, Nadja , Branca, Mattia , Thierstein, Marc, Büchi, Annina Elisabeth , Güntensperger, Dominik , Tinguely, Caroline , Theel, Elitza S. , Berbari, Elie F. , Niederhauser, Christoph , Büchi, Annina Elisabeth , Sendi, Parham , Blum, Manuel R. , Baldan, Rossella , Heg, Dik , Tande, Aaron J. , Endimiani, Andrea , Gowland, Peter

No container title available | March 27, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.167989329.99688527/v1 Get It

Objectives In a COVID-19 sero-surveillance cohort study with predominantly healthy and vaccinated individuals, the objectives were (i) to investigate longitudinally the factors associated with the quantitative dynamics of anti-spike IgG antibody levels, (ii) to evaluate whether the antibody levels were associated with protection from SARS-CoV-2 infection and (iii) to assess whether the association was different in the pre-Omicron compared with the Omicron period. Methods The QuantiVac Euroimmun ELISA test was used to quantify anti-S1 IgG levels. The entire study period (16 months), the 11-month pre-Omicron period and the cross-sectional analysis prior to the Omicron surge included 3219, 2310 and 895 reactive serum samples from 949, 919 and 895 study participants, respectively. Mixed-effect linear, mixed-effect time-to-event and logistic regression models were used to achieve the objectives. Results Age and time since infection or vaccination were the only factors associated with a decline of anti-S1 IgG levels. Antibody levels were significantly associated with protection from SARS-CoV-2 infection, and the association was higher for the Omicron than for the Alpha and Delta variants. In a prediction model, it was estimated that >8000 BAU/mL anti-S1 IgG was required to reduce the risk of infection with Omicron variants by 20% to 30% for 90 days. Conclusions Anti-S1 IgG antibody levels are associated with protection from infection. The levels in the pre-Omicron periods were less significant than during the Omicron surge, which in turn required very high levels for protection in a statistical model.
JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management
Gangat, Naseema , Szuber, Natasha , Tefferi, Ayalew , Szuber, Natasha

American Journal of Hematology | March 26, 2023 | Volume: 98 | Issue: 6 | Pages: 965-981

10.1002/ajh.26920 | PMID 36966432 Get It

Abstract Disease Overview JAK2 unmutated or non‐polycythemia vera (PV) erythrocytosis encompasses a heterogenous spectrum of hereditary and acquired entities. Diagnosis Foremost in the evaluation of erythrocytosis is the exclusion of PV through JAK2 (inclusive of exons 12–15) mutation screening. Initial assessment should also include gathering of previous records on hematocrit (Hct) and hemoglobin (Hgb) levels, in order to streamline the diagnostic process by first distinguishing longstanding from acquired erythrocytosis; subsequent subcategorization is facilitated by serum erythropoietin (Epo) measurement, germline mutation screening, and review of historical data, including comorbid conditions and medication list. Hereditary erythrocytosis constitutes the main culprit in the context of longstanding erythrocytosis, especially when associated with a positive family history. In this regard, a subnormal serum Epo level suggests EPO receptor mutation. Otherwise, considerations include those associated with decreased (high oxygen affinity Hgb variants, 2,3‐bisphosphoglycerate deficiency, PIEZO1 mutations, methemoglobinemia) or normal oxygen tension at 50% Hgb saturation (P50). The latter include germline oxygen sensing pathway ( HIF2A–PHD2–VHL ) and other rare mutations. Acquired erythrocytosis commonly results from central (e.g., cardiopulmonary disease, high‐altitude habitat) or peripheral (e.g., renal artery stenosis) hypoxia. Other noteworthy conditions associated with acquired erythrocytosis include Epo‐producing tumors (e.g., renal cell carcinoma, cerebral hemangioblastoma) and drugs (e.g., testosterone, erythropoiesis stimulating agents, sodium‐glucose cotransporter‐2 inhibitors). Idiopathic erythrocytosis is an ill‐defined terminology that presumes the existence of an increased Hgb/Hct level without an identifiable etiology. Such classification often lacks accounting for normal outliers and is marred by truncated diagnostic evaluation. Management Current consensus treatment guidelines are not supported by hard evidence and their value is further undermined by limited phenotypic characterization and unfounded concerns for thrombosis. We are of the opinion that cytoreductive therapy and indiscriminate use of phlebotomy should be avoided in the treatment of non‐clonal erythrocytosis. However, it is reasonable to consider therapeutic phlebotomy if one were to demonstrate value in symptom control, with frequency determined by symptoms rather than Hct level. In addition, cardiovascular risk optimization and low dose aspirin is often advised. Future Directions Advances in molecular hematology might result in better characterization of “idiopathic erythrocytosis” and expansion of the repertoire for germline mutations in hereditary erythrocytosis. Prospective controlled studies are needed to clarify potential pathology from JAK2 unmutated erythrocytosis, as well as to document the therapeutic value of phlebotomy.
Multi‐institutional experience with COVID‐19 convalescent plasma in children
Jacquot, Cyril , Noland, Daniel K., Donowitz, Jeffrey R. , Levy, Emily R. , Willis, Zachary , Rimland, Casey A. , Loi, Michele , Arrieta, Antonio , Drapeau, Noelle, Osborne, Stephanie , Zivick, Elise, Delaney, Meghan , Levy, Emily R , Arora, Satyam , Delaney, Meghan , Jacquot, Cyril , Gordon, Oren M. , Jain, Sanjay K. , Annen, Kyle , Ardura, Monica I. , Arora, Satyam

Transfusion | March 25, 2023 | Volume: 63 | Issue: 5 | Pages: 918-924

10.1111/trf.17318 | PMID 36965173 Get It

AbstractBackground and ObjectivesConvalescent COVID‐19 plasma (CCP) was developed and used worldwide as a treatment option by supplying passive immunity. Adult studies suggest administering high‐titer CCP early in the disease course of patients who are expected to be antibody‐negative; however, pediatric experience is limited. We created a multi‐institutional registry to characterize pediatric patients (<18 years) who received CCP and to assess the safety of this intervention.MethodsA REDCap survey was distributed. The registry collected de‐identified data including demographic information (age, gender, and underlying conditions), COVID‐19 disease features and concurrent treatments, CCP transfusion and safety events, and therapy response.ResultsNinety‐five children received CCP: 90 inpatients and 5 outpatients, with a median age of 10.2 years (range 0–17.9). They were predominantly Latino/Hispanic and White. The most frequent underlying medical conditions were chronic respiratory disease, immunosuppression, obesity, and genetic syndromes. CCP was primarily given as a treatment (95%) rather than prophylaxis (5%). Median total plasma dose administered and transfusion rates were 5.0 ml/kg and 2.6 ml/kg/h, respectively. The transfusions were well‐tolerated, with 3 in 115 transfusions reporting mild reactions. No serious adverse events were reported. Severity scores decreased significantly 7 days after CCP transfusion or at discharge. Eighty‐five patients (94.4%) survived to hospital discharge. All five outpatients survived to 60 days.ConclusionsCCP was found to be safe and well‐tolerated in children. CCP was frequently given concurrently with other COVID‐19‐directed treatments with improvement in clinical severity scores ≥7 days after CCP, but efficacy could not be evaluated in this study.
Socioeconomic status, race, and preadolescent acne: A population‐based retrospective cohort analysis in a mixed rural–urban community of the United States (Olmsted County, Minnesota)
Baisi, Katinna E. Rodriguez , Weaver, Amy L. , Shakshouk, Hadir , Tollefson, Megha M. , Rodriguez Baisi, Katinna , Shakshouk, H , Wi, Chung‐Il

Pediatric Dermatology | March 25, 2023 | Volume: 40 | Issue: 3 | Pages: 460-465

10.1111/pde.15294 | PMID 36965126 Get It

AbstractBackground/ObjectiveThere is limited information about the potential relationship of socioeconomic status (SES) with acne in preadolescents. Our objective was to assess the possible relationship between SES and preadolescent acne.MethodsA population‐based retrospective cohort study was conducted to identify Olmsted County, Minnesota, residents with an initial acne diagnosis between 7 and ≤12 years old during 2010 to 2018 using the Rochester Epidemiology Project. For each acne case, we randomly selected 2 sex‐ and age‐matched controls without an acne diagnosis from the county. Individual HOUsing‐based SocioEconomic Status index (HOUSES) derived from real property data was used to evaluate SES, represented as four quartiles with higher quartile representing higher SES.ResultsA total of 604 patients met the criteria. HOUSES distribution significantly differed between cases and controls (p = .001); a higher proportion of acne cases were in quartile 4 (42.2% vs. 32.7%), indicating higher SES. Race and ethnicity did not significantly differ between cases and controls. Among cases and controls, 74.5% and 72.3% were White, respectively. Study limitations include its retrospective design, only patients who visited a physician were included, and Olmsted County residents are largely non‐Hispanic White.ConclusionPreadolescents diagnosed with acne have a higher SES than those without diagnosed acne, highlighting a potential disparity in access to care and appropriate diagnosis.
Old Dog, New Tricks: A Review of Identifying and Addressing Youth Cannabis Vaping in the Pediatric Clinical Setting
Sharma, Pravesh , Mathews, Doug B, Nguyen, Quang Anh , Rossmann, Gillian, A Patten, Christi, Sharma, Pravesh , Patten, Christi A. , Hammond, Christopher J.

Clinical Medicine Insights: Pediatrics | March 25, 2023 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/11795565231162297 | PMID 36993933 Get It

Cannabis vaping has emerged as a predominant mode of cannabis use among United States (US) adolescents and young adults (AYA) primarily due to the popularity of modifiable designs of vaping devices coupled with changes in cannabis policies and increased availability of cannabinoid products. New methods for cannabis vaping by e-liquid/oil vaping, dry plant vaping, and cannabis concentrate vaping (ie, dabbing) have had high uptake among American youth with unclear long-term health implications. Issues with contamination, mislabeling, and expansion of the vaped cannabis market to include not only delta-9-tetrahydrocannabinol (delta-9-THC) and cannabidiol (CBD) but also delta-9-THC analogs (eg, delta-8 and delta-10) sold as hemp-derived “legal highs” further complicated this healthcare space. Recent research suggests that cannabis/THC vaping carries distinct and overlapping risks when compared to cannabis smoking and may be associated with greater risk for acute lung injuries, seizures, and acute psychiatric symptoms. Primary care clinicians providing care for AYA are in an ideal position to identify cannabis misuse and intervene early to address cannabis vaping. To improve public health outcomes, a need exists for pediatric clinicians to be educated about different ways/methods that youth are vaping cannabinoid products and associated risks related to cannabinoid vaping. Further, pediatric clinicians need to be trained how to effectively screen for and discuss cannabis vaping with their youth patients. In the current article, we present a clinically focused review of cannabis vaping among young people with 3 main aims to: (1) identify and describe the cannabis vaping products commonly used by American youth; (2) review the health correlates of youth cannabis vaping; and (3) discuss clinical considerations related to identifying and treating youth who vape cannabis.
4 A prospective study of hypertrophic cardiomyopathy and sleep disordered breathing
Venkataraman, Shreyas , Karim, Shahid

ACHD/Valve Disease/Pericardial Disease/Cardiomyopathy | March 24, 2023 | Volume: No volume available | Issue: No issue available | Pages: A3-A4

10.1136/heartjnl-2020-bcs.4 Get It

Bridge to Arrest Infarct Growth
Lin, Michelle , Anisetti, Bhrugun , Lin, Michelle P

Neurology | March 24, 2023 | Volume: 100 | Issue: 20 | Pages: 939-940

10.1212/wnl.0000000000207383 | PMID 36963839 Get It

Analysis of Left Ventricular Indexes and Mortality Among Asian Adults With Hemodynamically Significant Chronic Aortic Regurgitation
Lee, Chien‐Chang , Su, Chin‐Hua , Kitano, Tetsuji , Tsai, Chieh-Mei , Nishimura, Kunihiro , Lo, Hao-Yun, Hsu, Ron‐Bin , Chen, Yih‐Sharng , Chen, Wen‐Jone , Mankad, Rekha , Chen, Yih-Sharng , Yang, Li‐Tan , Amano, Masashi , Nabeshima, Yosuke , Hung, Chung‐Lieh , Nakaoku, Yuriko , Ogata, Soshiro , Lo, Hao-Yun, Pellikka, Patricia A. , Ho, Yi‐Lwun , Takeuchi, Masaaki , Izumi, Chisato

JAMA Network Open | March 24, 2023 | Volume: 6 | Issue: 3 | Pages: e234632

10.1001/jamanetworkopen.2023.4632 | PMID 36961461 Get It

ImportanceChronic hemodynamically significant aortic regurgitation (AR) is associated with excess risk of death, yet data for Asian patients are lacking, and whether Asian patients can abide by Western guidelines as to when aortic valve surgery should be performed is unknown.ObjectiveTo assess AR presentation and cutoffs of left ventricular ejection fraction (LVEF), LV end-systolic dimension index (LVESDi), and LV end-systolic volume index (LVESVi) that are associated with risk of death in Asian patients with AR.Design, Setting, and ParticipantsThis retrospective cohort study included consecutive patients with chronic, moderately severe to severe AR from 3 tertiary referral centers (2 in Japan and 1 in Taiwan) from June 11, 2008, through November 19, 2020, with follow-up through November 11, 2021.ExposuresAortic regurgitation severity, graded by a comprehensive integrated approach.Main Outcomes and MeasuresThe primary outcome was the association between volume-derived LVEF, LVESDi, and LVESVi and all-cause death (ACD). The secondary outcome was the association of these LV indexes with cardiovascular death (CVD). Clinical and echocardiographic data were analyzed retrospectively. A de novo disk-summation method was used to derive LV volumes and volume-derived LVEF.ResultsOf 1259 patients (mean [SD] age, 64 [17] years; 934 [74%] male), 515 (41%) were Japanese and 744 (59%) were Taiwanese. The median follow-up was 4.1 years (IQR, 1.56-7.24 years). The mean (SD) body surface area was 1.67 (0.21) m2; LVEF, 55% (11%); LVESDi, 24.7 (5.7) mm/m2; LVESVi, 50.1 (28.0) mL/m2; and indexed mid–ascending aorta size, 24.7 (5.5) mm/m2. Aortic valve surgery occurred in 483 patients (38%); 240 patients (19%) died during follow-up. Overall mean (SD) 8-year survival was 74% (2%). Separate multivariate models adjusted for covariates demonstrated independent associations of LVEF, LVESDi, and LVESVi with ACD (LVEF: hazard ratio [HR] per 10%, 0.80; 95% CI, 0.70-0.92; P = .002; LVESDi: HR, 1.04; 95% CI, 1.01-1.06; P = .002; LVESVi: HR per 10 mL/m2, 1.11; 95% CI, 1.05-1.17; P &amp;lt; .001) and CVD (LVEF: HR per 10%, 0.69; 95% CI, 0.56-0.85; P &amp;lt; .001; LVESDi: HR, 1.05; 95% CI, 1.01-1.09; P = .01; LVESVi per 10 mL/m2: HR, 1.15; 95% CI, 1.06-1.24; P &amp;lt; .001). In the total cohort, spline curves showed that mortality started to increase for an LVEF of 53% or less, LVESDi of 22 mm/m2 or greater, and LVESVi of 46 mL/m2 or greater for both ACD and CVD. Early surgery was beneficial in 3 strata of LVESDi (&amp;lt;20, 20 to &amp;lt;25, and ≥25 mm/m2) and 2 strata of LVESVi (&amp;lt;46 and ≥46 mL/m2).Conclusions and RelevanceThis multicenter cohort study of Asian patients with hemodynamically significant AR found cutoff values of LVEF, LVESDi, and LVESVi that were associated with increased risk of death. These findings suggest that Western guidelines seem applicable in Asian patients and, most importantly, that indexed LV parameters with a lower cutoff could be used in discriminating patients with excess mortality risk.
Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period—a cross-sequential study based on COVAD surveys
Jagtap, Kshitij , Naveen, R, Day, Jessica , Sen, Parikshit , Vaidya, Binit , Nune, Arvind , Nikiphorou, Elena , Tan, Ai Lyn , Agarwal, Vishwesh , Saha, Sreoshy , Ziadé, Nelly , Velikova, Tsvetelina , Milchert, Marcin , Parodis, Ioannis , Kuwana, Masataka , Makol, Ashima , Patel, Aarat , Pauling, John D , Wincup, Chris , Tehozol, Erick Adrian Zamora , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Goo, Phonpen Akawatcharangura , Shumnalieva, Russka , Kibbi, Lina El , Halabi, Hussein , Shaharir, Syahrul Sazliyana , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Salim, Babur , Gheita, Tamer A. , Group, COVAD Study, Kardeş, Sinan , Schreiber, Karen, Vince, Melinda Nagy, Singh, Yogesh Preet , Ranjan, Rajiv , Jain, Avinash , Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Ghodke, Akanksha, Fazal, Zoha Zahid , Yıldırım, Reşit , Atzeni, Fabiola , Bocci, Elena Bartoloni, Sebastiani, Marco, Orsolini, Giovanni , Angelis, Rossella De , Danielli, Maria Giovanna, Grignaschi, Silvia, Alluno, Alessia, Ioannone, Florenzo, Prieto‐González, Sergio , Nakashima, Ran , Sato, Shinji , Kaneko, Yuko , Gono, Takahisa, Tomaras, Stylianos , Aharonov, Or, Bouchti, I. El , Baba, Zineb, Maurier, François, Meyer, Alain , Limaye, Vidya , Hudson, Marie , Landon‐Cardinal, Océane , Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Harifi, Ghita, Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, Nunez, Lilith Stange, Vergara, M Cristian, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Argueta, Sandra, Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, Escalante, Miguel , Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Ravichandran, Naveen , Gupta, Latika , Naveen, R , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Joshi, Mrudula , Velikova, Tsvetelina , Milchert, Marcin , Parodis, Ioannis , Gracia-Ramos, Abraham Edgar , Cavagna, Lorenzo , Kuwana, Masataka , Knitza, Johannes , Makol, Ashima , Pauling, John D , Wincup, Chris , Barman, Bhupen , Zamora Tehozol, Erick Adrian , Rojas Serrano, Jorge , García-De La Torre, Ignacio , Colunga-Pedraza, Iris J , Merayo-Chalico, Javier , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Shumnalieva, Russka , Chen, Yi-Ming , Hoff, Leonardo Santos , El Kibbi, Lina , Halabi, Hussein , Sazliyana Shaharir, Syahrul , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero-Uribe, Carlo Vinicio , Lilleker, James B , Salim, Babur , Gheita, Tamer , Chatterjee, Tulika , Saavedra, Miguel A , Distler, Oliver , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Agarwal, Vishwesh , Day, Jessica , Tan, Ai Lyn , Nune, Arvind , Sen, Parikshit , Saha, Sreoshy , Jagtap, Kshitij , De Angelis, Rossella , Singh, Yogesh Preet , Shinjo, Samuel Katsuyuki , Joshi, Mrudula , Gracia‐Ramos, Abraham Edgar , Torre, Ignacio García‐De La , Colunga-Pedraza, I. J. , Chen, Yi‐Ming , Chatterjee, Tulika , Distler, Oliver , Group, COVAD Study, Griger, Zoltán , Andréoli, Laura , Lini, Daniele , Schreiber, Karen , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Pande, Arun K. , Chandwar, Kunal , Boro, Hiya , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Papa, Nicoletta Del , Sambataro, Gianluca , Govoni, Marcello , Parisi, Simone , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco, Quartuccio, Luca , Franceschini, Franco , Sainaghi, Pier Paolo , Venerito, Vincenzo , Giollo, Alessandro , Fornaro, Marco , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Loarce‐Martos, Jesus , Gonzalez, Raquel Aranega, Yoshida, Akira , Kimura, Naoki, Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Hmamouchi, Ihsane , Baba, Zineb, Giannini, Margherita , Maurier, F. , Campagne, Julien , Langguth, Daman , Needham, Merrilee , Srivastav, Nilesh , Arbeláez-Cortés, Álvaro , Cajas, Javier, Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , Doskaliuk, Bohdana , Ima-Edomwonyi, Uyi, Emorinken, Airenakho , Olaosebikan, Hakeem , So, Ho , Ugarte‐Gil, Manuel F. , Mohammed, Reem Hamdy A , Harifi, Ghita , Fuentes-Silva, Yurilís , Salinas, Rodrigo Nicolás Garcia , Aggarwal, Rohit

Rheumatology | March 24, 2023 | Volume: 62 | Issue: 12 | Pages: 3838-3848

10.1093/rheumatology/kead144 | PMID 36961331 Get It

Abstract Objective Flares of autoimmune rheumatic diseases (AIRDs) following COVID-19 vaccination are a particular concern in vaccine-hesitant individuals. Therefore, we investigated the incidence, predictors and patterns of flares following vaccination in individuals living with AIRDs, using global COVID-19 Vaccination in Autoimmune Diseases (COVAD) surveys. Methods The COVAD surveys were used to extract data on flare demographics, comorbidities, COVID-19 history, and vaccination details for patients with AIRDs. Flares following vaccination were identified as patient-reported (a), increased immunosuppression (b), clinical exacerbations (c) and worsening of PROMIS scores (d). We studied flare characteristics and used regression models to differentiate flares among various AIRDs. Results Of 15 165 total responses, the incidence of flares in 3453 patients with AIRDs was 11.3%, 14.8%, 9.5% and 26.7% by definitions a–d, respectively. There was moderate agreement between patient-reported and immunosuppression-defined flares (K = 0.403, P = 0.022). Arthritis (61.6%) and fatigue (58.8%) were the most commonly reported symptoms. Self-reported flares were associated with higher comorbidities (P = 0.013), mental health disorders (MHDs) (P &lt; 0.001) and autoimmune disease multimorbidity (AIDm) (P &lt; 0.001). In regression analysis, the presence of AIDm [odds ratio (OR) = 1.4; 95% CI: 1.1, 1.7; P = 0.003), or a MHD (OR = 1.7; 95% CI: 1.1, 2.6; P = 0.007), or being a Moderna vaccine recipient (OR = 1.5; 95% CI: 1.09, 2.2; P = 0.014) were predictors of flares. Use of MMF (OR = 0.5; 95% CI: 0.3, 0.8; P = 0.009) and glucocorticoids (OR = 0.6; 95% CI: 0.5, 0.8; P = 0.003) were protective. A higher frequency of patients with AIRDs reported overall active disease post-vaccination compared with before vaccination (OR = 1.3; 95% CI: 1.1, 1.5; P &lt; 0.001). Conclusion Flares occur in nearly 1 in 10 individuals with AIRDs after COVID vaccination; people with comorbidities (especially AIDm), MHDs and those receiving the Moderna vaccine are particularly vulnerable. Future avenues include exploring flare profiles and optimizing vaccine strategies for this group.
CORR Insights®: Is Prolonged Use of Antibiotic Prophylaxis and Postoperative Antithrombotic and Antispasmodic Treatments Necessary After Digit Replantation or Revascularization?
Dennison, David G.

Clinical Orthopaedics & Related Research | March 24, 2023 | Volume: 481 | Issue: 8 | Pages: 1595-1596

10.1097/corr.0000000000002616 | PMID 36961212 Get It